信达生物ASCO点评:IBI363彰显成为下一代免疫疗法的潜力

招银国际
Jun 05

一、IBI363在ASCO会议上的表现信达生物的IBI363在2025年ASCO会议上共有三项口头报告,公布了非小细胞肺癌、结直肠癌和黑色素瘤的1/2期临床数据。这些数据体现了IBI363在免疫治疗耐药人群以及冷肿瘤中的优秀疗效,特别是显著的总生存期(OS)获益趋势,显示出长期生存潜力。二、IBI363在非小细胞肺癌中的疗效IBI363在免疫耐药的鳞状非小细胞肺癌中展现了优异的疗效,单药治疗在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10